165 related articles for article (PubMed ID: 27148585)
1. Putative BRAF activating fusion in a medullary thyroid cancer.
Kasaian K; Wiseman SM; Walker BA; Schein JE; Hirst M; Moore RA; Mungall AJ; Marra MA; Jones SJ
Cold Spring Harb Mol Case Stud; 2016 Mar; 2(2):a000729. PubMed ID: 27148585
[TBL] [Abstract][Full Text] [Related]
2. New drugs for medullary thyroid cancer: new promises?
Spitzweg C; Morris JC; Bible KC
Endocr Relat Cancer; 2016 Jun; 23(6):R287-97. PubMed ID: 27185870
[TBL] [Abstract][Full Text] [Related]
3. Personalized Medicine in Medullary Thyroid Carcinoma: A Broad Review of Emerging Treatments.
Martins RS; Jesus TT; Cardoso L; Soares P; Vinagre J
J Pers Med; 2023 Jul; 13(7):. PubMed ID: 37511745
[TBL] [Abstract][Full Text] [Related]
4. Molecular Targeted Therapies of Aggressive Thyroid Cancer.
Ferrari SM; Fallahi P; Politti U; Materazzi G; Baldini E; Ulisse S; Miccoli P; Antonelli A
Front Endocrinol (Lausanne); 2015; 6():176. PubMed ID: 26635725
[TBL] [Abstract][Full Text] [Related]
5. RAS proto-oncogene in medullary thyroid carcinoma.
Moura MM; Cavaco BM; Leite V
Endocr Relat Cancer; 2015 Oct; 22(5):R235-52. PubMed ID: 26285815
[TBL] [Abstract][Full Text] [Related]
6. Evaluating vandetanib in the treatment of medullary thyroid cancer: patient-reported outcomes.
Fallahi P; Ferrari SM; Elia G; Ragusa F; Paparo SR; Ruffilli I; Patrizio A; Materazzi G; Antonelli A
Cancer Manag Res; 2019; 11():7893-7907. PubMed ID: 31686907
[TBL] [Abstract][Full Text] [Related]
7. Update on the cytologic and molecular features of medullary thyroid carcinoma.
Pusztaszeri MP; Bongiovanni M; Faquin WC
Adv Anat Pathol; 2014 Jan; 21(1):26-35. PubMed ID: 24316908
[TBL] [Abstract][Full Text] [Related]
8. Targeted Therapy for Medullary Thyroid Cancer: A Review.
Priya SR; Dravid CS; Digumarti R; Dandekar M
Front Oncol; 2017; 7():238. PubMed ID: 29057215
[TBL] [Abstract][Full Text] [Related]
9. An Era of Advances in Systemic Therapies for Advanced Thyroid Cancer.
Yun KM; Cohen EEW
JCO Oncol Pract; 2024 Mar; ():OP2300747. PubMed ID: 38452309
[TBL] [Abstract][Full Text] [Related]
10. Recent Updates on the Management of Medullary Thyroid Carcinoma.
Kim BH; Kim IJ
Endocrinol Metab (Seoul); 2016 Sep; 31(3):392-399. PubMed ID: 27586449
[TBL] [Abstract][Full Text] [Related]
11. Surgical management of medullary thyroid cancer.
Mazeh H; Sippel RS
Minerva Endocrinol; 2012 Dec; 37(4):329-34. PubMed ID: 23235189
[TBL] [Abstract][Full Text] [Related]
12. Current Concepts in the Molecular Genetics and Management of Thyroid Cancer: An Update for Radiologists.
Kelil T; Keraliya AR; Howard SA; Krajewski KM; Braschi-Amirfarzan M; Hornick JL; Ramaiya NH; Tirumani SH
Radiographics; 2016; 36(5):1478-93. PubMed ID: 27618325
[TBL] [Abstract][Full Text] [Related]
13. Multikinase Inhibitors for the Treatment of Progressive, Metastatic Medullary Thyroid Cancer - An Evolving Paradigm.
Jarzab B; Krajewska J
Eur Endocrinol; 2014 Aug; 10(2):145-150. PubMed ID: 29872479
[TBL] [Abstract][Full Text] [Related]
14. Cellular signaling pathway alterations and potential targeted therapies for medullary thyroid carcinoma.
Giunti S; Antonelli A; Amorosi A; Santarpia L
Int J Endocrinol; 2013; 2013():803171. PubMed ID: 23509459
[TBL] [Abstract][Full Text] [Related]
15. Treating medullary thyroid cancer in the age of targeted therapy.
Cabanillas ME; Hu MI; Jimenez C; Grubbs EG; Cote GJ
Int J Endocr Oncol; 2014; 1(2):203-216. PubMed ID: 25908961
[TBL] [Abstract][Full Text] [Related]
16. The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells.
Akeno-Stuart N; Croyle M; Knauf JA; Malaguarnera R; Vitagliano D; Santoro M; Stephan C; Grosios K; Wartmann M; Cozens R; Caravatti G; Fabbro D; Lane HA; Fagin JA
Cancer Res; 2007 Jul; 67(14):6956-64. PubMed ID: 17638907
[TBL] [Abstract][Full Text] [Related]
17. Novel Targeted Therapies for Metastatic Thyroid Cancer-A Comprehensive Review.
Al-Jundi M; Thakur S; Gubbi S; Klubo-Gwiezdzinska J
Cancers (Basel); 2020 Jul; 12(8):. PubMed ID: 32751138
[TBL] [Abstract][Full Text] [Related]
18. Treatment of advanced thyroid cancer with targeted therapies: ten years of experience.
Viola D; Valerio L; Molinaro E; Agate L; Bottici V; Biagini A; Lorusso L; Cappagli V; Pieruzzi L; Giani C; Sabini E; Passannati P; Puleo L; Matrone A; Pontillo-Contillo B; Battaglia V; Mazzeo S; Vitti P; Elisei R
Endocr Relat Cancer; 2016 Apr; 23(4):R185-205. PubMed ID: 27207700
[TBL] [Abstract][Full Text] [Related]
19. Beyond RET: potential therapeutic approaches for advanced and metastatic medullary thyroid carcinoma.
Santarpia L; Ye L; Gagel RF
J Intern Med; 2009 Jul; 266(1):99-113. PubMed ID: 19522829
[TBL] [Abstract][Full Text] [Related]
20. Synergistic effect of oncogenic RET and loss of p18 on medullary thyroid carcinoma development.
van Veelen W; van Gasteren CJ; Acton DS; Franklin DS; Berger R; Lips CJ; Höppener JW
Cancer Res; 2008 Mar; 68(5):1329-37. PubMed ID: 18316595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
